The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

The following is a summary of "Novel devices and biomarkers in screening for esophageal squamous cell cancer," published in ...

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.

Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular ...

During a live event, Benjamin Garmezy, MD, discussed combinations regimens used for patients with renal cell carcinoma after ...

Bavencio as first-line maintenance was associated with long-term efficacy in advanced urothelial carcinoma regardless of ...

DelveInsight's Merkel Cell Carcinoma Market Insights report includes a comprehensive understanding of current treatment ...

Are there key genes involved in TKI resistance in ccRCC? What mechanisms are associated with this development? A research team, led by Professor Ben Liu from the Department of Urology at the First ...

Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: hint of major added benefit. Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new drug ...